Plasmalogens are a specialized class of phospholipids — fatty compounds embedded in cell membranes — that have attracted growing scientific interest for their proposed roles in brain function, cellular energy metabolism, and antioxidant defense. Dr. Dayan Goodenowe, a biochemist and founder of Prodrome Sciences, has spent roughly two decades studying these molecules, arguing that declining plasmalogen levels are a measurable early feature of neurodegenerative conditions including Alzheimer’s disease.
Prodrome Sciences markets plasmalogen precursor supplements and a diagnostic blood index designed to assess an individual’s plasmalogen status. This article explains the underlying science as accurately as possible, identifies what the peer-reviewed literature currently supports, and is honest about where evidence remains preliminary or complicated by commercial interests.
Key Takeaways
- Plasmalogens are ether-linked phospholipids found abundantly in brain, heart, and immune tissue, where they likely serve antioxidant and membrane-structural functions.
- Circulating ethanolamine plasmalogen levels are measurably lower in Alzheimer’s disease patients and correlate with cognitive performance and CSF tau, suggesting they are meaningful biomarkers [1].
- Breast milk plasmalogen content is associated with infant neurodevelopmental outcomes and body composition, indicating these lipids matter from early life onward [2].
- Prodrome Sciences supplements provide alkylglycerol precursors for the body to convert into plasmalogens, but whether this raises brain tissue concentrations meaningfully in humans is not yet proven by large independent trials.
- The underlying science is legitimate and evolving; the commercial testing and supplementation program requires independent replication before it can be recommended as a clinical intervention.
What Are Plasmalogens?
Plasmalogens are ether-linked phospholipids — a structurally distinct subclass of the phospholipid family that forms cell membranes. Unlike standard phospholipids, which attach fatty acid chains via ester bonds, plasmalogens use a vinyl ether bond at the sn-1 carbon position. This structural difference is functionally important: the vinyl ether linkage is highly reactive toward oxidants, meaning plasmalogens may act as sacrificial antioxidants that absorb oxidative damage and protect surrounding membrane components from reactive oxygen species.
Plasmalogens are most concentrated in tissues with high metabolic demands and significant oxidative exposure — particularly the brain, heart muscle, and immune cells. Beyond antioxidant protection, they are thought to influence membrane fluidity, support the function of embedded signaling proteins, and participate in cellular lipid metabolism. Because plasmalogens are synthesized primarily in peroxisomes, any impairment of peroxisomal function reduces their production.
Dr. Goodenowe's Research Background and Prodrome Sciences
Dr. Dayan Goodenowe holds a doctorate in biochemistry and has published peer-reviewed work in metabolomics and lipid biomarker science. His central hypothesis, developed over approximately two decades, is that circulating ethanolamine plasmalogens (PlsEtn) decline measurably before the clinical onset of Alzheimer’s disease and several other age-related conditions, potentially making them useful early biomarkers and therapeutic targets.
Prodrome Sciences, the company he founded, developed a blood-based plasmalogen index test intended to compare an individual’s PlsEtn levels against age-matched reference norms. The company also markets plasmalogen precursor supplements, primarily based on alkylglycerols derived from shark liver oil, which the body can theoretically use to resynthesize plasmalogens through its own enzymatic pathways. Consumers should be aware that Goodenowe holds a dual role as researcher and company founder — his scientific credentials are genuine, but this relationship warrants extra attention to independent replication when evaluating commercial claims.
Plasmalogens and Alzheimer's Disease: What the Research Shows
The most substantive published evidence linking plasmalogen indices to neurological outcomes involves measurements of circulating PlsEtn in patients with diagnosed Alzheimer’s disease. Research published in Alzheimer’s and Dementia found that circulating ethanolamine plasmalogen indices were significantly lower in individuals with Alzheimer’s disease compared to healthy controls, and that these indices correlated with measures of cognition and with cerebrospinal fluid tau — a recognized Alzheimer’s pathology biomarker [1]. This is a meaningful finding: plasmalogen deficiency appears to track with disease severity, not merely presence.
A key unanswered question concerns directionality. Does declining plasmalogen synthesis contribute to neurodegeneration — for instance, by reducing membrane integrity and antioxidant defense in neurons — or does neurodegeneration reduce plasmalogen production as a downstream consequence of cellular damage? Current evidence is associative rather than causal. No large, independent, randomized controlled trial has confirmed that raising plasmalogen levels in humans prevents cognitive decline or reverses Alzheimer’s pathology. The association documented in published research is real and warrants serious investigation, but it does not by itself validate a commercial treatment.
Plasmalogens Across the Lifespan: Maternal and Infant Evidence
Plasmalogen research extends well beyond aging and dementia. A study examining maternal predictors of breast milk plasmalogen content found that plasmalogen levels in breast milk were associated with differences in infant body composition and neurodevelopmental outcomes [2]. This suggests these lipids contribute meaningfully to early neural development, and that a mother’s nutritional status, body composition, and metabolic health influence how much of these lipids an infant receives during a critical developmental window.
These findings reinforce the hypothesis that plasmalogens are biologically relevant across the entire human lifespan — not only in older adults experiencing neurodegeneration. They also raise a practical point: dietary and lifestyle factors that support healthy plasmalogen metabolism in mothers may have downstream effects on offspring neurodevelopment, a direction that deserves further rigorous study.
How Prodrome Sciences Supplementation Is Supposed to Work
Goodenowe’s supplementation strategy does not involve delivering intact plasmalogens. Intact plasmalogen phospholipids are largely hydrolyzed in the gastrointestinal tract before reaching systemic circulation in a form the body can use. Instead, Prodrome Sciences products supply alkylglycerol precursors — specifically 1-O-alkyl-sn-glycerols — that can enter the ether-lipid biosynthesis pathway in peroxisomes and be enzymatically converted into plasmalogens by the body.
The rationale is analogous to supplying a biochemical pathway with an upstream building block rather than the finished product. Whether oral precursor supplementation meaningfully raises plasmalogen concentrations in the brain or cardiac tissue in living humans is a question the current evidence has not definitively answered. Animal studies and Goodenowe’s own open-label human data show measurable effects on circulating plasmalogen indices in blood, but the relationship between peripheral blood measurements and concentrations in neural tissue is not fully established by independent human trials.
Honest Assessment: Evidence Strengths and Limitations
The plasmalogen field rests on legitimate cell biology, and the association between low plasmalogen indices and Alzheimer’s disease is documented in peer-reviewed literature [1]. These are genuine scientific contributions. However, consumers and clinicians evaluating the Prodrome Sciences program specifically should weigh several important limitations.
Most published data on the commercial Prodrome protocol — the specific blood test and alkylglycerol dosing regimen — comes from studies authored or co-authored by Goodenowe or his group. Conflict-of-interest disclosure does not invalidate research, but independent replication by unaffiliated laboratories and neutral funding sources is the standard that separates a promising hypothesis from a validated clinical tool. That independent validation, at the scale and rigor required for medical guidance, has not yet been completed.
No regulatory agency — the U.S. FDA, the European EMA, or equivalent bodies — has approved plasmalogen supplementation as a treatment or prevention for any disease. The Prodrome Sciences index is a wellness tool, not a cleared medical diagnostic. Individuals with neurological concerns, peroxisomal disorders, significant metabolic conditions, or who are pregnant or breastfeeding should speak with a qualified physician rather than self-directing based on a commercial blood test and supplement protocol.
🛒 Where to Buy Shilajit
- Pürblack Live ResinLab-tested / studied
resin, ~300-500 mg/day — Premium purified resin, third-party heavy-metal tested; widely regarded as a reference-quality resin. - Toniiq Shilajit
capsules, 500 mg — Standardized fulvic-acid %, third-party tested generic. - Nutricost Shilajit Extract
capsules, 500 mg — Low-cost large-count bottles. - Double Wood Shilajit
capsules, 500 mg — Budget-friendly, COA on request.
As an Amazon Associate we earn from qualifying purchases. Shilajit quality varies widely — always choose a product with a published third-party heavy-metal test (COA) before buying.
A Note on the Evidence
The evidence connecting plasmalogen biology to neurological health is scientifically grounded but still developing, and no regulatory body has approved plasmalogen supplementation as a treatment or prevention for any disease; individuals with neurological conditions, peroxisomal disorders, significant metabolic disease, or who are pregnant or breastfeeding should consult a qualified physician before considering any plasmalogen testing or supplementation.
Frequently Asked Questions
Who is Dr. Dayan Goodenowe and what is Prodrome Sciences?
Dr. Dayan Goodenowe is a biochemist with a background in metabolomics who has spent approximately two decades researching plasmalogen phospholipids as biomarkers and potential therapeutic targets in neurodegeneration. Prodrome Sciences is the company he founded to commercialize a plasmalogen index blood test and alkylglycerol precursor supplements. His dual role as researcher and company founder means published claims from his group, while peer-reviewed, should be assessed with attention to potential commercial bias and the importance of independent replication.
What does the peer-reviewed evidence say about plasmalogens and Alzheimer's disease?
Published research in Alzheimer’s and Dementia found that circulating ethanolamine plasmalogen indices are significantly lower in Alzheimer’s disease patients compared to healthy controls, and that these indices correlate with cognitive measures and cerebrospinal fluid tau levels [1]. This supports plasmalogens as meaningful disease biomarkers, though the causal direction — whether deficiency drives pathology or results from it — remains unresolved.
Are plasmalogens relevant only to older adults?
No. Research examining breast milk plasmalogen content found that higher maternal plasmalogen levels were associated with differences in infant neurodevelopment and body composition [2], indicating these lipids are functionally important from early life through aging. Plasmalogens are also studied in the context of heart disease and immune function, though evidence quality varies across these areas.
Why don't plasmalogen supplements just contain plasmalogens directly?
Intact plasmalogens are largely broken down during digestion before reaching circulation in usable form. The Prodrome Sciences approach supplies alkylglycerol precursors — upstream building blocks — that the body can theoretically convert into plasmalogens through peroxisomal enzymatic pathways. While this mechanism is biochemically plausible, whether oral supplementation meaningfully raises plasmalogen concentrations in brain tissue specifically has not been confirmed in large, independent, blinded human trials.
Has Goodenowe's research been independently replicated?
The broader association between low plasmalogen levels and Alzheimer’s disease appears in research not exclusively produced by Goodenowe’s group, and the cell biology of ether-linked phospholipids is well established in scientific literature. However, the specific commercial protocol — the Prodrome index test and alkylglycerol supplementation regimen as a wellness intervention — has not been validated by large, independent, double-blind randomized controlled trials, which is the evidence standard expected for medical applications.
Is the Prodrome Sciences plasmalogen index test a medical diagnostic?
No. The Prodrome Sciences index is presented as a wellness assessment, not a medical diagnostic cleared or approved by regulatory agencies such as the FDA or EMA. While circulating ethanolamine plasmalogen measurement is a scientifically grounded biomarker used in research contexts [1], translating a research biomarker into a validated clinical diagnostic requires regulatory evaluation that has not been completed for this specific commercial test.
References
- Kling MA et al. Circulating ethanolamine plasmalogen indices in Alzheimer's disease: Relation to diagnosis, cognition, and CSF tau. Alzheimer's & dementia : the journal of the Alzheimer's Association (2020). PMID 32715599
- Ramadurai S et al. Maternal Predictors of Breast Milk Plasmalogens and Associations with Infant Body Composition and Neurodevelopment. Clinical therapeutics (2022). PMID 35909001
As an Amazon Associate we earn from qualifying purchases.